 NEW YORK and LONDON, July 01, 2020 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Akari or the Company AKTX, a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement andor leukotriene systems are implicated, today announced the appointment of Torsten Hombeck, Ph.D., as Chief Financial Officer and member of the Companys executive team. Dr. Hombeck has over two decades of biopharmaceutical industry experience in financial management and strategic planning, including several senior executive positions where he was responsible for finance, strategy, business and corporate development, and commercialization primarily in the U.S. Dr. Hombeck will be based out of Akaris New York City office and will also be responsible for investor relations and business development. 